Key Highlights

  • The FDA agreed that ReNerve's chosen preclinical evaluation model is appropriate and gave guidance on the control groups it expects.
  • The FDA also set out biochemical and biophysical testing expectations to support a future regulatory submission.
  • ReNerve will finalise its testing plan and data package, and has not yet given a timing for the planned submission.

ReNerve Limited (ASX:RNV), an Australian medical device company focused on peripheral nerve repair, announced on 14 October 2026 that it held a positive pre-submission meeting with the US Food and Drug Administration on 30 September 2026 for its NervAlign Nerve Guide Matrix (NGM) program.

Purpose of the meeting

The pre-submission meeting, supported by written feedback, gave ReNerve the chance to discuss its regulatory plan for the NGM with the FDA before making a formal submission. The company says the discussions confirmed its submission strategy while also providing feedback from the regulator. The meeting does not itself clear or approve the product.

FDA feedback

The FDA agreed that the model ReNerve has chosen for its preclinical evaluation is appropriate and provided additional guidance on the control groups it expects. It also set out clear expectations for the biochemical and biophysical data needed to support clearance. ReNerve says it is reviewing the feedback in detail and will use it to finalise its testing plan and the data package for the NGM, which means additional testing may be required beyond what the company has completed.

Manufacturing and preclinical status

Manufacturing of the NGM continues with ReNerve's contract Manufacturing organisation (CMO), and the company says it will update the market on progress, including the timing of the planned submission. It refers to positive results from an ongoing preclinical study, but no results are included in this release.

Product portfolio

ReNerve's flagship product on the market is the FDA-cleared NervAlign Nerve Cuff, a bioabsorbable protective wrap absorbed within six months of surgery. The company cites a clinical study in which post-surgical pain scores fell from 7.1 to 0.4 with the cuff, compared with 7.1 to 3.3 without it. It also markets Empliq deep dermal and amniotic tissue products.

In development are the NervAlign Nerve Conduit Range, for short gaps between nerve ends, and the NervAlign Nerve Guide Matrix, described as a customised, ready-to-use alternative to existing nerve grafts for longer gaps. The release gives no regulatory timetable or Revenue information.

Company and product background

ReNerve describes itself as founded by a neurosurgeon and MedTech researchers and focused on peripheral nerve injuries. Its on-market range comprises the NervAlign Nerve Cuff, the Empliq deep dermal tissue product and three Empliq amniotic tissue ranges. In development, the NervAlign Nerve Conduit Range uses eCOO technology in a material designed to facilitate nerve growth over short gaps, and the Nerve Guide Matrix is aimed at longer gaps between nerve ends.

Why the pre-submission step matters

A pre-submission meeting allows a sponsor to test its testing and evidence plan before filing, so the feedback shapes what ReNerve must still complete. The FDA's expectations on control groups and biochemical and biophysical data may add work or time, and the company has not provided a revised timetable. Its comment that the feedback is encouraging given its preclinical study results refers to a study that remains ongoing and unreported here.